Yvonne L. Latour
Yvonne L. Latour has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Alain P. Gobert
Vanderbilt University Medical Center
5 shared publications - Keith T. Wilson
Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
5 shared publications - Daniel P. Barry
Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
4 shared publications - Margaret M. Allaman
Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Vanderbilt University Medical Center, Nashville, USA
4 shared publications - Maria Blanca Piazuelo
Vanderbilt University Medical Center
4 shared publications - Alberto Delgado
Centro de Electrnica Industrial, Universidad Politcnica de Madrid, Madrid, Spain
3 shared publications
Latest Publications
- 6 July 2023
- Published by Elsevier in Gastroenterology
- Vol. 164 (6)
Tu1233 DELETION OF ACONITATE DECARBOXYLASE 1 EXACERBATES EXPERIMENTAL COLITIS AND IS ASSOCIATED WITH A DYSBIOTIC MICROBIOME
- 6 July 2023
- Published by Elsevier in Gastroenterology
- Vol. 164 (6)
Tu1233 DELETION OF ACONITATE DECARBOXYLASE 1 EXACERBATES EXPERIMENTAL COLITIS AND IS ASSOCIATED WITH A DYSBIOTIC MICROBIOME
- Open Access
- 22 June 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (12)
Cystathionine γ-lyase exacerbates Helicobacter pylori immunopathogenesis by promoting macrophage metabolic remodeling and activation
Macrophages play a crucial role in the inflammatory response to the human stomach pathogen Helicobacter pylori , which infects half of the world’s population and causes gastric cancer. Recent studies have highlighted the importance of macrophage immunometabolism in their activation state and function. We have demonstrated that the cysteine-producing enzyme cystathionine γ-lyase (CTH) is upregulated in humans and mice with H. pylori infection. Here, we show that induction of CTH in macrophages by H. pylori promoted persistent inflammation. Cth –/– mice had reduced macrophage and T cell activation in H. pylori –infected tissues, an altered metabolome, and decreased enrichment of immune-associated gene networks, culminating in decreased H. pylori –induced gastritis. CTH is downstream of the proposed antiinflammatory molecule, S -adenosylmethionine (SAM). Whereas Cth –/– mice exhibited gastric SAM accumulation, WT mice treated with SAM did not display protection against H. pylori –induced inflammation. Instead, we demonstrated that Cth -deficient macrophages exhibited alterations in the proteome, decreased NF-κB activation, diminished expression of macrophage activation markers, and impaired oxidative phosphorylation and glycolysis. Thus, through altering cellular respiration, CTH is a key enhancer of macrophage activation, contributing to a pathogenic inflammatory response that is the universal precursor for the development of H. pylori –induced gastric disease.
- 22 June 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (12)
Open AccessCystathionine γ-lyase exacerbates Helicobacter pylori immunopathogenesis by promoting macrophage metabolic remodeling and activation
Macrophages play a crucial role in the inflammatory response to the human stomach pathogen Helicobacter pylori , which infects half of the world’s population and causes gastric cancer. Recent studies have highlighted the importance of macrophage immunometabolism in their activation state and function. We have demonstrated that the cysteine-producing enzyme cystathionine γ-lyase (CTH) is upregulated in humans and mice with H. pylori infection. Here, we show that induction of CTH in macrophages by H. pylori promoted persistent inflammation. Cth –/– mice had reduced macrophage and T cell activation in H. pylori –infected tissues, an altered metabolome, and decreased enrichment of immune-associated gene networks, culminating in decreased H. pylori –induced gastritis. CTH is downstream of the proposed antiinflammatory molecule, S -adenosylmethionine (SAM). Whereas Cth –/– mice exhibited gastric SAM accumulation, WT mice treated with SAM did not display protection against H. pylori –induced inflammation. Instead, we demonstrated that Cth -deficient macrophages exhibited alterations in the proteome, decreased NF-κB activation, diminished expression of macrophage activation markers, and impaired oxidative phosphorylation and glycolysis. Thus, through altering cellular respiration, CTH is a key enhancer of macrophage activation, contributing to a pathogenic inflammatory response that is the universal precursor for the development of H. pylori –induced gastric disease.
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
Tu1513: CELL-SPECIFIC ROLE OF TALIN-1 IN COLITIS
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
Tu1513: CELL-SPECIFIC ROLE OF TALIN-1 IN COLITIS
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
Tu1525: THE ROLE OF ACOD1 IN REGULATING CITROBACTER RODENTIUM IMMUNOPATHOGENESIS
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
Tu1525: THE ROLE OF ACOD1 IN REGULATING CITROBACTER RODENTIUM IMMUNOPATHOGENESIS
- Open Access
Rapid Identification of New Biomarkers for the Classification of GM1 Type 2 Gangliosidosis Using an Unbiased 1H NMR-Linked Metabolomics Strategy
Biomarkers currently available for the diagnosis, prognosis, and therapeutic monitoring of GM1 gangliosidosis type 2 (GM1T2) disease are mainly limited to those discovered in targeted proteomic-based studies. In order to identify and establish new, predominantly low-molecular-mass biomarkers for this disorder, we employed an untargeted, multi-analyte approach involving high-resolution 1H NMR analysis coupled to a range of multivariate analysis and computational intelligence technique (CIT) strategies to explore biomolecular distinctions between blood plasma samples collected from GM1T2 and healthy control (HC) participants (n = 10 and 28, respectively). The relationship of these differences to metabolic mechanisms underlying the pathogenesis of GM1T2 disorder was also investigated. 1H NMR-linked metabolomics analyses revealed significant GM1T2-mediated dysregulations in ≥13 blood plasma metabolites (corrected p < 0.04), and these included significant upregulations in 7 amino acids, and downregulations in lipoprotein-associated triacylglycerols and alanine. Indeed, results acquired demonstrated a profound distinctiveness between the GM1T2 and HC profiles. Additionally, employment of a genome-scale network model of human metabolism provided evidence that perturbations to propanoate, ethanol, amino-sugar, aspartate, seleno-amino acid, glutathione and alanine metabolism, fatty acid biosynthesis, and most especially branched-chain amino acid degradation (p = 10−12−10−5) were the most important topologically-highlighted dysregulated pathways contributing towards GM1T2 disease pathology. Quantitative metabolite set enrichment analysis revealed that pathological locations associated with these dysfunctions were in the order fibroblasts > Golgi apparatus > mitochondria > spleen ≈ skeletal muscle ≈ muscle in general. In conclusion, results acquired demonstrated marked metabolic imbalances and alterations to energy demand, which are consistent with GM1T2 disease pathogenesis mechanisms.
Open AccessRapid Identification of New Biomarkers for the Classification of GM1 Type 2 Gangliosidosis Using an Unbiased 1H NMR-Linked Metabolomics Strategy
Biomarkers currently available for the diagnosis, prognosis, and therapeutic monitoring of GM1 gangliosidosis type 2 (GM1T2) disease are mainly limited to those discovered in targeted proteomic-based studies. In order to identify and establish new, predominantly low-molecular-mass biomarkers for this disorder, we employed an untargeted, multi-analyte approach involving high-resolution 1H NMR analysis coupled to a range of multivariate analysis and computational intelligence technique (CIT) strategies to explore biomolecular distinctions between blood plasma samples collected from GM1T2 and healthy control (HC) participants (n = 10 and 28, respectively). The relationship of these differences to metabolic mechanisms underlying the pathogenesis of GM1T2 disorder was also investigated. 1H NMR-linked metabolomics analyses revealed significant GM1T2-mediated dysregulations in ≥13 blood plasma metabolites (corrected p < 0.04), and these included significant upregulations in 7 amino acids, and downregulations in lipoprotein-associated triacylglycerols and alanine. Indeed, results acquired demonstrated a profound distinctiveness between the GM1T2 and HC profiles. Additionally, employment of a genome-scale network model of human metabolism provided evidence that perturbations to propanoate, ethanol, amino-sugar, aspartate, seleno-amino acid, glutathione and alanine metabolism, fatty acid biosynthesis, and most especially branched-chain amino acid degradation (p = 10−12−10−5) were the most important topologically-highlighted dysregulated pathways contributing towards GM1T2 disease pathology. Quantitative metabolite set enrichment analysis revealed that pathological locations associated with these dysfunctions were in the order fibroblasts > Golgi apparatus > mitochondria > spleen ≈ skeletal muscle ≈ muscle in general. In conclusion, results acquired demonstrated marked metabolic imbalances and alterations to energy demand, which are consistent with GM1T2 disease pathogenesis mechanisms.
- Top Cited Papers
- 23 April 2019
- Published by Springer Nature in Amino Acids
- Vol. 52 (2) , 151-160
The role of polyamines in the regulation of macrophage polarization and function
Naturally occurring polyamines are ubiquitously distributed and play important roles in cell development, amino acid and protein synthesis, oxidative DNA damage, proliferation, and cellular differentiation. Macrophages are essential in the innate immune response, and contribute to tissue remodeling. Naïve macrophages have two major potential fates: polarization to (1) the classical pro-inflammatory M1 defense response to bacterial pathogens and tumor cells, and (2) the alternatively activated M2 response, induced in the presence of parasites and wounding, and also implicated in the development of tumor-associated macrophages. ODC, the rate-limiting enzyme in polyamine synthesis, leads to an increase in putrescine levels, which impairs M1 gene transcription. Additionally, spermidine and spermine can regulate translation of pro-inflammatory mediators in activated macrophages. In this review, we focus on polyamines in macrophage activation patterns in the context of gastrointestinal inflammation and carcinogenesis. We seek to clarify mechanisms of innate immune regulation by polyamine metabolism and potential novel therapeutic targets.
- 23 April 2019
- Published by Springer Nature in Amino Acids
- Vol. 52 (2) , 151-160
Top Cited PapersThe role of polyamines in the regulation of macrophage polarization and function
Naturally occurring polyamines are ubiquitously distributed and play important roles in cell development, amino acid and protein synthesis, oxidative DNA damage, proliferation, and cellular differentiation. Macrophages are essential in the innate immune response, and contribute to tissue remodeling. Naïve macrophages have two major potential fates: polarization to (1) the classical pro-inflammatory M1 defense response to bacterial pathogens and tumor cells, and (2) the alternatively activated M2 response, induced in the presence of parasites and wounding, and also implicated in the development of tumor-associated macrophages. ODC, the rate-limiting enzyme in polyamine synthesis, leads to an increase in putrescine levels, which impairs M1 gene transcription. Additionally, spermidine and spermine can regulate translation of pro-inflammatory mediators in activated macrophages. In this review, we focus on polyamines in macrophage activation patterns in the context of gastrointestinal inflammation and carcinogenesis. We seek to clarify mechanisms of innate immune regulation by polyamine metabolism and potential novel therapeutic targets.
- Open Access
- 1 April 2017
- Published by Elsevier in Molecular Therapy
- Vol. 25 (4) , 892-903
Novel Biomarkers of Human GM1 Gangliosidosis Reflect the Clinical Efficacy of Gene Therapy in a Feline Model
- 1 April 2017
- Published by Elsevier in Molecular Therapy
- Vol. 25 (4) , 892-903
Open AccessNovel Biomarkers of Human GM1 Gangliosidosis Reflect the Clinical Efficacy of Gene Therapy in a Feline Model
- 8 December 2015
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 170 (3) , 634-644
MRI/MRS as a surrogate marker for clinical progression in GM1 gangliosidosis
Background GM1 gangliosidosis is a lysosomal storage disorder caused by mutations in GLB1, encoding β‐galactosidase. The range of severity is from type I infantile disease, lethal in early childhood, to type III adult onset, resulting in gradually progressive neurological symtpoms in adulthood. The intermediate group of patients has been recently classified as having type II late infantile subtype with onset of symptoms at one to three years of age or type II juvenile subtype with symptom onset at 2–10 years. To characterize disease severity and progression, six Late infantile and nine juvenile patients were evaluated using magnetic resonance imaging (MRI), and MR spectroscopy (MRS). Since difficulties with ambulation (gross motor function) and speech (expressive language) are often the first reported symptoms in type II GM1, patients were also scored in these domains. Deterioration of expressive language and ambulation was more rapid in the late infantile patients. Fourteen MRI scans in six Late infantile patients identified progressive atrophy in the cerebrum and cerebellum. Twenty‐six MRI scans in nine juvenile patients revealed greater variability in extent and progression of atrophy. Quantitative MRS demonstrated a deficit of N‐acetylaspartate in both the late infantile and juvenile patients with greater in the late infantile patients. This correlates with clinical measures of ambulation and expressive language. The two subtypes of type II GM1 gangliosidosis have different clinical trajectories. MRI scoring, quantitative MRS and brain volume correlate with clinical disease progression and may serve as important minimally‐invasive outcome measures for clinical trials.
- 8 December 2015
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 170 (3) , 634-644
MRI/MRS as a surrogate marker for clinical progression in GM1 gangliosidosis
Background GM1 gangliosidosis is a lysosomal storage disorder caused by mutations in GLB1, encoding β‐galactosidase. The range of severity is from type I infantile disease, lethal in early childhood, to type III adult onset, resulting in gradually progressive neurological symtpoms in adulthood. The intermediate group of patients has been recently classified as having type II late infantile subtype with onset of symptoms at one to three years of age or type II juvenile subtype with symptom onset at 2–10 years. To characterize disease severity and progression, six Late infantile and nine juvenile patients were evaluated using magnetic resonance imaging (MRI), and MR spectroscopy (MRS). Since difficulties with ambulation (gross motor function) and speech (expressive language) are often the first reported symptoms in type II GM1, patients were also scored in these domains. Deterioration of expressive language and ambulation was more rapid in the late infantile patients. Fourteen MRI scans in six Late infantile patients identified progressive atrophy in the cerebrum and cerebellum. Twenty‐six MRI scans in nine juvenile patients revealed greater variability in extent and progression of atrophy. Quantitative MRS demonstrated a deficit of N‐acetylaspartate in both the late infantile and juvenile patients with greater in the late infantile patients. This correlates with clinical measures of ambulation and expressive language. The two subtypes of type II GM1 gangliosidosis have different clinical trajectories. MRI scoring, quantitative MRS and brain volume correlate with clinical disease progression and may serve as important minimally‐invasive outcome measures for clinical trials.